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Neurotrophin (NT) receptors are coupled to numerous signaling networks that play critical roles in
neuronal survival and plasticity. Several non-peptide small molecule ligands have recently been reported
that bind to and activate speciﬁc tropomyosin-receptor kinase (Trk) NT receptors, stimulate their
downstream signaling, and cause biologic effects similar to, though not completely overlapping, those of
the native NT ligands. Here, in silico screening, coupled with low-throughput neuronal survival screening,
identiﬁed a compound, LM22B-10, that, unlike prior small molecule Trk ligands, binds to and activates
TrkB as well as TrkC. LM22B-10 increased cell survival and strongly accelerated neurite outgrowth, su-
perseding the effects of brain-derived neurotrophic factor (BDNF), NT-3 or the two combined. Addi-
tionally, unlike the NTs, LM22B-10 supported substantial early neurite outgrowth in the presence of
inhibiting glycoproteins. Examination of the mechanisms of these actions suggested contributions of the
activation of both Trks and differential interactions with p75NTR, as well as a requirement for involve-
ment of the Trk extracellular domain. In aged mice, LM22B-10 activated hippocampal and striatal TrkB
and TrkC, and their downstream signaling, and increased hippocampal dendritic spine density. Thus,
LM22B-10 may constitute a new tool for the study of TrkB and TrkC signaling and their interactions with
p75NTR, and provides groundwork for the development of ligands that stimulate unique combinations of
Trk receptors and activity patterns for application to selected neuronal populations and deﬁcits present
in various disease states.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), and neurotrophin-3 (NT-3) are members of the neuro-
trophin (NT) protein family that act through their cognate
tropomyosin-receptor kinase (Trk) receptors (NGF/TrkA, BDNF/
TrkB, NT-3/TrkC) and the common NT receptor p75 (p75NTR). NTand Neurological Sciences,
rive, Room H3160, Stanford,
an Francisco Veterans Affairs
lement St., San Francisco, CA
Massa), longo@stanford.edu
ork.
Ltd. This is an open access article usignaling via Trks strongly inﬂuences neuronal survival, differen-
tiation and synaptic function via phospholipase Cg1 (PLCg),
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-
kinase pathways (PI3K) (Chao, 2003; Huang and Reichardt, 2003;
Kaplan and Miller, 2000; Longo and Massa, 2013). Numerous
neurologic diseases and conditions exhibit constituent alterations
in expression and/or function of NTs or their receptors, and show
mitigation of pathology and/or symptoms inmodel systems treated
with agents that modulate NT receptor activity (see (Longo and
Massa, 2013) for review). Moreover, several groups have identi-
ﬁed small molecules that interact with Trks or p75NTR and induce
downstream signaling and biologic effects, including, TrkA activa-
tors: compound D3 (Maliartchouk et al., 2000), gambogic amide
(Jang et al., 2007), and MT2; TrkB activators: 7,8-dihydroxyﬂavone
(Jang et al., 2010b), deoxygedunin (Jang et al., 2010a), and LM22A-4
(Massa et al., 2010); TrkB activity inhibitor ANA-12 (Cazorla et al.,
2011); and p75NTR modulators: LM11A-31, LM11A-24 (Massander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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metic TrkC ligands have been reported, some of which differentially
promote neurite outgrowth and survival (Chen et al., 2009; Zaccaro
et al., 2005). The mechanisms and applications of these compounds
and their derivatives remain areas of active investigation.
We previously identiﬁed selective TrkB ligands (Massa et al.,
2010) that bind to the extracellular domain of TrkB, promote
neuronal survival, and activate AKT and ERK pathways in a TrkB-
dependent fashion. One of these, LM22A-4, has been shown to
promotemotor recovery after ischemic stroke (Han et al., 2012) and
traumatic brain injury (Massa et al., 2010), and to rescue TrkB
phosphorylation deﬁcits, improve respiratory function and acutely
reverse spontaneous apnea and other respiratory abnormalities in a
mouse model of Rett syndrome (Schmid et al., 2012; Kron et al.,
2014). In addition, LM22A-4 reduced TrkB signaling deﬁcits, mo-
tor impairment, and neuropathology in two Huntington’s Disease
mouse models (Simmons et al., 2013), promoted TrkB activation
and differentiation in cementoblasts in vitro (Kajiya et al., 2014),
and stimulated TrkB activation in intestinal smooth muscle cells
and enhanced cholinergic-induced intestinal contraction (Al-
Qudah et al., 2014). In the present study, in silico screening with a
pharmacophore based on the BDNF loop II domain, coupled with
low-throughput in vitro neurotrophic assays, unexpectedly yielded
a small molecule with binding selectivity for both TrkB and TrkC
and signaling and biological effects distinct from those stimulated
by BDNF or NT-3.
2. Material and methods
2.1. Materials
LY294002, K252a, PD98059, PP2 and U73132 were purchased
from Calbiochem (La Jolla, CA); adenosine and pituitary adenylate
cyclase-activating polypeptide 27 (PACAP27) were purchased from
Sigma (St. Louis, MO); and recombinant BDNF and NT-3 from
PeproTech (Rocky Hill, NJ). LM22B-10 (2-[[4-[[4-[Bis-(2-hydroxy-
ethyl)-amino]-phenyl]-(4-chloro-phenyl)-methyl]-phenyl]-(2-
hydroxy-ethyl)-amino]-ethanol) was custom manufactured by
Ricerca Biosciences LLC (Concord, OH). Each preparation was
characterized by high-performance liquid chromatography (HPLC),
nuclear magnetic resonance spectrometry and liquid chromatog-
raphy/mass spectrometry (LC-MS) and had a purity of greater than
97.8%. The molecular weight and formula of the compound were
further conﬁrmed in our laboratory by high-resolution MS. For use
in vitro, LM22B-10 was dissolved in 0.04 N HCl prior to dilution
(1:10,000) in culture medium. For in vivo intraperitoneal (IP)
administration, LM22B-10 in 0.04 N HCl was mixed with Cremo-
phor (Sigma) and 2X phosphate buffered saline (2X PBS; Sigma).
This solution was adjusted to pH 5 to yield 1X PBS (0.01 M sodium
phosphate; 0.138 M NaCl; 0.0027 M KCl) containing 0.02 N HCl and
2.5% Cremophor. Mouse monoclonal anti-phospho-ERKT202/Y204,
rabbit polyclonal anti-ERK42/44, mouse monoclonal anti-phospho-
AKTS473, rabbit polyclonal anti-AKT, rabbit polyclonal anti-TrkC,
rabbit monoclonal anti-p75NTR, rabbit polyclonal anti-Shc, site-
speciﬁc rabbit polyclonal anti-TrkY490 and site-speciﬁc rabbit
polyclonal anti-TrkY674/675 were obtained from Cell Signaling
Technology, Inc. (Beverly, MA); rabbit polyclonal anti-phospho-
TrkBY515 and rabbit polyclonal anti-phospho-TrkCY820 were from
Novus Biologicals (Littleton, CO); rat monoclonal anti-p75NTR, rab-
bit polyclonal anti-phospho-TrkAY791and rabbit polyclonal anti-
synaptophysin were from Abcam Inc., (Cambridge, MA); mouse
monoclonal anti-PSD95 and chondroitin sulfate proteoglycans
(CSPG) were from Millipore (Billerica, MA); rabbit polyclonal TrkA
and TrkB antibodies were from Upstate USA, Inc. (Charlottesville,
VA); rabbit p75NTR polyclonal antibody andmouse anti-b-tubulin IIIantibodywere from Promega (Madison,WI); rabbit polyclonal anti-
phospho-PKCS660 and rabbit polyclonal anti-phospho-TrkBY817
were from Epitomics (Burlingame, CA); mouse monoclonal TrkB
antibody was from BD Transduction Laboratories (Lexington, KY);
TrkC rabbit polyclonal, pan-Trk rabbit polyclonal (sc-11) and pY99
mouse monoclonal (sc-7020) antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA); rabbit polyclonal anti-phospho-
TrkBY705 was from Signalway Antibody (College Park, MD); poly-
clonal anti-phospho-TrkCY516 was from Assay BioTech (Sunnyvale,
CA); and rabbit p75NTR polyclonal antibody, was a gift from Moses
Chao (New York University). Rabbit recombinant chimeric proteins
TrkA-Fc, TrkB-Fc, TrkC-Fc, p75NTR-Fc and myelin-associated glyco-
protein-Fc (MAG-Fc) were from R&D Systems (Minneapolis, MN);
and protein A-linked Dynabeads™ and recombinant human NGF
were from Invitrogen (San Diego, CA). HPLC vials were from Na-
tional Scientiﬁc (Rockwood, TN), and a Pinnacle DB biphenyl
(50 mm length, 2.1 ID, 3 mm particle size) column was from Restek
(Bellefonte, PA). Other chemicals were purchased from Sigma-
Aldrich Corp (St. Louis, MO), unless otherwise stated.
2.2. Construction of chimeric TrkA-TrkB receptors
Rat full-length wild-type (WT) TrkB, and TrkA/B-1.4B and 4.1B
chimeric expression vectors were custom made at Vigene Bio-
sciences, Inc. (Rockville, MD), as described previously (Perez et al.,
1995; Zaccaro et al., 2001). TrkA/B-1.4B contains the entire rat
TrkA extracellular domain fused to the rat TrkB intracellular
domain. In TrkA/B-4.1B constructs, the TrkB IgG-C2 domain is
replaced with the TrkA IgG-C2 domain, and the resulting sequence
contains cysteine clusters 1 and 2 (Cys 1, 2), a leucine motif (LRM),
and the IgG-C1 domain of TrkB, the IgG-C2 domain of TrkA, and the
intracellular domain of TrkB. All chimeric constructs were
conﬁrmed by sequencing and were cloned into the pENTER
expression vector that contains a CMV promoter and selection gene
providing resistance to kanamycin (Vigene Biosciences, Inc.).
2.3. Primary neuronal cultures and cell survival assays
Hippocampal neuron cultures were prepared from embryonic
day 16 (E16) CF1 mouse fetuses, as described previously (Walter
et al., 2011; Yang et al., 2006). Under the low density conditions
used here, neuronal survival is dependent, in part, on addition of
exogenous NTs (Lindholm et al., 1996; Walter et al., 2011). LM22B-
10 was dissolved in water containing 0.04 N HCl and diluted in
culture medium to a ﬁnal dilution of 1:10,000 HCl. For controls, HCl
was diluted in culture media in equivalent amounts. Cell survival
following a 48 h exposure to BDNF or LM22B-10 was measured by
morphological criteria using staining for b-tubulin III antibody
which allows visualization of neurites and cell bodies (Massa et al.,
2006; Walter et al., 2011), quantiﬁcation of ATP levels using the
ViaLight assay (Lonza Group Ltd., Rockland, ME), or by terminal
deoxynucleotidyl transferase-mediated biotinylated UTP nick end
labeling (TUNEL) with DAPI staining (Walter et al., 2011; Yang et al.,
2006, 2008). Dose-response curves were generated with SigmaPlot
(Systat Software Inc., San Jose, CA).
2.4. Neurite outgrowth assay
Mouse E16 dissociated hippocampal neurons were seeded on
poly-L-lysine-coated coverslips in 12 well plates at a density of
4  104 cells/well. Neurons were treated with control medium,
BDNF, NT-3 and/or LM22B-10 or co-treated with MAG-Fc at 25 mg/
ml or CSPG at 1 mg/ml. For the MAG and CSPG assays, culture me-
dium contained 0.1% fetal bovine serum (FBS). For 7, 14 and 21 day
in vitro neurite assays, culture mediumwas changed to Neurobasal/
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Culture mediumwas changed every three days with the addition of
fresh NTs and compound. Cultures were maintained for either 24 h
(for the MAG and CSPG assay) or 48 h (for antibody inhibition ex-
periments and others), or other time points, then ﬁxed with 4%
paraformaldehyde (PFA), and stained with anti-b-tubulin III anti-
body. Neurite length was measured using Neurolucida software
(v.10, MBF Biosciences). Random images, 5e10 for each condition,
from 3 independent experiments were measured. For survival and
neurite outgrowth inhibitor studies standard concentrations from
published works were used, with ﬁnal concentrations of: 200 nM
K252a, 10 mM LY294002, 50 mM PD98059, 10 mM PP2 and 1 mM
U73132, in addition to 0.7 nM BDNF, 0.7 nM NT-3 and/or 1000 nM
LM22B-10. For antibody inhibition studies, TrkB, TrkC, or p75NTR
(rat monoclonal or rabbit polyclonal) antibodies and control non-
immune serum were used at ﬁnal dilutions of 1:400 added
concomitantly with BDNF, NT-3 and/or LM22B-10.
2.5. Transfection
For p75NTR overexpression, control plasmid pDsRed (Clontech)
or p75NTR-RFP (Addgene, MA) was transfected into either 3T3-TrkB
or 3T3-TrkC cells using Lipofectamine™ 3000 (Invitrogen), ac-
cording to the manufacturer’s instructions, as described previously
(Yang et al., 2006). Cells were exposed to 0.7 nM BDNF, 0.7 nM NT-3
or 1000 nM LM22B-10 for 96 h, followed by the ViaLight survival
assay, as described above. For p75NTR siRNA expression in hippo-
campal neurons, control siRNA or p75NTR siRNA (Santa Cruz) was
transfected into mouse hippocampal neurons 2 h after cell seeding
using Lipofectamine® RNAiMAX (Invitrogen), according to the
manufacturer’s instructions. Cell survival following 48 h exposure
to BDNF, NT-3 or LM22B-10 was measured by morphological
criteria using staining for b-tubulin III antibody (Massa et al., 2006;
Walter et al., 2011). For EGFP expression in hippocampal neurons,
reporter plasmid (EGFP) was transfected into 14 DIV mouse hip-
pocampal neurons using Lipofectamine 3000. After transfection,
culture medium was changed to Neurobasal/B27 medium with or
without the addition of BDNF or LM22B-10 for 24 h. Cells were then
ﬁxed and dendritic spine density measured using Neurolucida. For
TrkA/B chimera transfection, human embryonic kidney 293 (HEK-
293) cells were cultured in Dulbecco’s modiﬁed Eagle Medium
(DMEM) supplemented with 10% FBS (Invitrogen) on 60 mm cul-
ture dishes. After plating in a 12 well plate, cells were changed to
serum freemedium once 60e70% conﬂuencewas reached and then
transiently transfected for 24 or 48 h using Lipofectamine 3000. In
each condition, a total of 2 or 4 mg of plasmid DNA was used. After
transfection the cells were treated with NGF (0.7 nM), BDNF
(0.7 nM) or LM22B-10 (1000 nM) for 1 h and then harvested for
Western blotting with anti-TrkY674/675 or pan-Trk antibodies.
2.6. NIH-3T3 cell cultures and cell survival assays
Mouse NIH-3T3 cells were obtained from ATCC (Manassas, VA),
mouse NIH-3T3 cells expressing TrkA (NIH-3T3-TrkA) or p75NTR
(NIH-3T3-p75NTR) were provided by Dr. William Mobley (Univer-
sity of California at San Diego), and NIH-3T3 cells expressing TrkB
(NIH-3T3-TrkB) or TrkC (NIH-3T3-TrkC) were provided by Dr. David
Kaplan (University of Toronto). Cells were propagated in DMEM
supplemented with 10% FBS and 200e400 mg/ml Geneticin (for Trk-
expressing cells) or 400 mg/ml hygromycin (for p75NTR-expressing
cells). Cells were seeded into 24-well plates (30,000 cells/well) and
cultured in medium consisting of 50% PBS and 50% DMEM without
supplements. Following exposure to growth factors (0.7 nM) or
1000 nM LM22B-10 for 72e96 h, cells were suspended in 50 ml lysis
buffer, transferred to opaque 96-well culture plates and survivalwas measured using the ViaLight Assay.2.7. Trk coupled bead-immobilization and LC-MS/MS LM22B-10
binding assay
To measure total LM22B-10 binding, each of the Fc-chimeric Trk
family receptors and p75NTR were bound on Protein A-decorated
Dynabeads™ and incubated with increasing concentrations of
LM22B-10. Beads (50 ml) were washed twice with binding buffer
(10 mM EDTA, 0.1% BSA, PBS, pH 7.4) then incubated with each
receptor at 1 mM in 50 ml of binding buffer for 1.5 h on an orbital
shaker (Thermolyne AROS 160) at room temperature with mixing/
agitation every 30 min. After resuspension in 100 ml of binding
buffer and spinning down to wash away unbound receptor, each
vial was incubated on a shaker overnight at 4 C in 100 ml binding
buffer containing LM22B-10 at concentrations of 0, 100, 250, 500,
750, 1000, 1500, or 2000 nM. Unbound LM22B-10 was washed
away with 100 ml of binding buffer and the vials were incubated
overnight at 37 C with trypsin in 20 mM ammonium acetate at a
trypsin-receptor ratio of 1:20 (w/w). To measure non-speciﬁc
binding, 50 ml of binding buffer was used instead of receptor so-
lution. The samples were then stored in 4 C. For LC-MS/MS anal-
ysis, 180 ml of 10% acetonitrile in milliQ water was added to each
vial, beads were mixed, the vials were centrifuged for 1 min at
3600 rpm at room temperature, and the supernatant transferred to
polypropylene HPLC vials. Each sample (30 ml) was injected into
either a Shimdadzu 20 series HPLC (Pleasanton, CA) or Agilent 1200
HPLC (Santa Clara, CA) with a Pinnacle DB biphenyl column, and
identiﬁed using a Q-Trap 4000 (AB Sciex, Foster City, CA) spec-
trometer in MRMmode. The peak areawas calculated using Analyst
software. Fractional binding was computed as: (total bound -
nonspeciﬁcally bound compound)/saturation value. Total bound
compound is the amount of compound released on trypsin treat-
ment and nonspeciﬁcally bound compound is the amount released
without trypsin treatment (in binding buffer). Saturation value is
the maximum amount of compound bound to the beads measured
on the day of analysis.2.8. Cell-based binding assay
NIH-3T3WTcells or NIH-3T3 cells expressing one of the four NT
receptors were seeded into poly-L-lysine-coated 96-well plates
(Fisher Scientiﬁc, Pittsburgh, PA). After reaching 85e95% conﬂu-
ence, Trk-expressing cells were incubated with their cognate NT
and p75NTR-expressing cells were incubated with BDNF, each at
multiple concentrations with or without 1000 nM LM22B-10 for
45 min at 4 C with gentle shaking. After one wash with ice-cold
PBS, cells were ﬁxed with 4% PFA for 15 min, rinsed twice with
PBS, and then incubated with anti-mouse monoclonal NGF anti-
body (1 mg/ml, Abcam, Cambridge, MA), anti-mouse monoclonal
BDNF antibody (1 mg/ml, Sigma), or anti-rabbit polyclonal NT-3
antibody (1 mg/ml, Abcam) for 1 h at room temperature. Cells
were then rinsed twice with PBS and incubated with DyLight 549-
conjugated secondary antibody (1:500, Jackson ImmunoResearch
Laboratory, Inc., West Grove, PA) for 1 h at room temperature fol-
lowed by two washes. Fluorescent signals were measured at an
excitation wavelength of 549 nm and emission of 568 nm using a
Molecular Devices plate reader (Sunnyvale, CA). Duplicate wells
were measured for each NT concentration. Background signal,
determined from wells containing 3T3-cells lacking NT receptors
incubated with a maximal level of NT, was subtracted. Data were
normalized according to the maximum signal and were expressed
as percentage of each NT maximum.
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To evaluate the speciﬁcity of LM22B-10, binding to a broad range
of pharmacologically relevant receptors was assessed, 57 total,
including numerous neurotransmitter and G-protein coupled re-
ceptors, using standard radioligand competition binding assays
(ExpressSProﬁle) performed by Cerep Inc. (Seattle, WA). Experi-
mental conditions are described on the Cerep website (www.cerep.
fr).
2.10. Hippocampal synaptosome enriched fraction preparation
Hippocampal synaptosomes were collected using a previously
published method (VanGuilder et al., 2010), with some modiﬁca-
tions. Brieﬂy, hippocampal tissue was harvested from C57BL/6J
mice (Jackson Laboratories, Bar Harbor, ME) at ages 15e17 months
following one month of LM22B-10 treatment (50 mg/kg/day
intraperitoneal (IP) and 5 mg/kg/day intranasal (IN)), rapidly
exposed to ice-cold sucrose buffer (TEVP buffer: 10 mM Tris-HCl,
pH 7.4, 320 mM sucrose, 4 mM HEPES, 1 mM Na3VO4, 1 mM
EDTA) and sonicated for 10 s. Homogenates were incubated on ice
for 30 min and then centrifuged to pellet the nuclear/cytoskeletal
fraction (4 C, 1000  g, 12 min). The resulting supernatants were
then centrifuged to pellet the synaptosomal fraction (4 C,
25,000  g, 30 min). Synaptosome samples were resuspended in a
detergent-based protein lysis buffer (100 mM NaCl, 20 mM HEPES,
1 mM EDTA, 1 mM dithiothreitol, 1.0% Triton, 1 mM Na3VO4) con-
taining a Complete Mini EDTA-free Protease Inhibitor Cocktail
Tablet (Roche Diagnostic GmbH, Mannheim, Germany) for every
10 ml lysis buffer and stored at 80 C.
2.11. Western blotting, immunoprecipitation, and kinase activity
assays
For assays of Trk, AKT, ERK and PKC activation, 3T3-TrkA, 3T3-
TrkB or 3T3-TrkC cells were seeded into 6 well plates and were
grown in DMEM supplemented with 10% FBS to 50e60% conﬂu-
ence, then switched to serum free medium consisting of 50% PBS
and 50% DMEMwithout supplements. Cells were exposed to NTs or
LM22B-10 for 48 h and then culture medium was switched to 50%
PBS/50% DMEM without NTs or LM22B-10 for 6 h. Next, cells were
treated with serum-free DMEM containing the same NT or com-
poundwithwhich they had been previously cultured, 0.7 nM of one
of the NTs or 1000 nM of LM22B-10 for 1 h. Cells were then har-
vested and used for Western blotting with phospho-speciﬁc anti-
bodies then membranes were re-probed with antibodies detecting
the total protein. All antibodies for immunoblotting were used at a
dilution of 1:1000, with the following exceptions: pAKT, AKT, pERK,
ERK were used at 1:2000; TrkB at 1:3000; PSD-95 and synapto-
physin at 1:10,000. In some cases, 80e100 mg/ml of extracted pro-
tein was immunoprecipitated with TrkB antibody (1:100; Millipore
07e225). Half of the precipitated proteinwas retained forWesterns
blots using the pY99 antibody (1:6000), which detects phosphor-
ylated tyrosine residues; the other half was used for kinase activity
assays using the Antibody Beacon Tyrosine Kinase Assay Kit (Invi-
trogen), according to manufacturer’s instructions. Hippocampal
neurons derived from E16 mice were cultured in poly-L-lysine
coated 6 well plates (Corning Inc.; 5  106 cells/well) in DMEM/F12
containing 10% FBS for 2 h, in Neurobasal/B27 medium for an
additional 44 h, and then in serum-free DMEM/F12 for 2 h. Finally,
NTs (0.7 nM), adenosine (100 mM), PACAP27 (100 nM), or LM22B-10
(1000 nM) with or without PP2 (10 mM) inhibitor were added for
1 h before cells were harvested and processed for western blot
analysis, as described previously (Walter et al., 2011; Yang et al.,
2003). For Shc adaptor protein assays, human cementoblast-likecells (HCEM; a gift from Dr. Kitagawa, Hiroshima University Hos-
pital, Japan) stably transfected with the telomerase catalytic sub-
unit hTERT gene, were cultured in a-minimum essential medium
(a-MEM, Sigma) supplemented with 10% FBS to 80e90% conﬂu-
ence. Prior to the addition of stimulants, the medium was changed
to a-MEM with 0.5% FBS, cells were incubated for 4 h and then
treated with BDNF (0.7 nM) or LM22B-10 (1000 nM) for 1 h.
Immunoprecipitation was performed with the TrkB antibody
(1:100), as described above, followed by immunoblotting with Shc
antibody (1:1000) or TrkB antibody (1:3000). To detect the
immunoblotted target protein bands without interference from
denatured IgG, the HRP-conjugated anti-rabbit IgG VeriBlot for IP
secondary antibody (Abcam, Cambridge, MA; 1:1000) was
employed.
2.12. Immunoﬂuorescent staining and quantiﬁcation
Cultured hippocampal neurons were ﬁxed in 4% PFA for 20 min,
permeabilized for 6 min with 80% ice-cold methanol, and then
incubated with the following primary antibodies: phospho-Trk
speciﬁc antibodies (1:500), MAP2 antibody AP20 (1:1000), or b-
tubulin III antibody (1:1000) in PBS. Secondary antibodies included
donkey anti-rabbit and anti-mouse conjugated with either FTIC or
Cy3 (1:400; Jackson ImmunoResearch Laboratories, Inc.). For
quantitative analysis, experimenters were blind to the treatment
conditions. Images were acquired with a 63 objective on a Leica
Confocal microscope. The total intensity of ﬂuorescent pixels was
measured using UN-Scan-it Gel & Graph Digitizing Software Ver.
6.14 (Silk Scientiﬁc, Inc.). Average pixel intensity ratios were
calculated as the total phospho-Trk signal divided by total number
of cells and the data were normalized to the signal from cells in
control culture medium.
2.13. LM22B-10-induced signaling in vivo
All animal procedures were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals using protocols approved by the Institutional Ani-
mal Care and Use Committee at Stanford University. These
protocols included efforts to minimize animal suffering and
numbers used. Adult male C57BL/6J mice (3 months of age) were
randomly divided into vehicle (PBS/Cremophor) and treatment
(LM22B-10 in PBS/Cremophor vehicle) groups. Intranasal (IN)
administration was performed by applying 10e15 ml into the right
naris 3-5 times at 2e4 min intervals, once daily for 1 week. Hip-
pocampal and striatal brain regions were harvested 1 h after the
last dose and processed for western blot analysis.
2.14. Modiﬁed Golgi staining and analysis of spine density
Mice were perfused with 0.9% heparinized saline and the brains
were impregnated with Modiﬁed Golgi-Cox Staining Solution
(developed and provided by Deqiang Jing and Francis Lee, Cornell
University) for 8e9 days at room temperature in the dark, as per-
formed previously (Han et al., 2012). The brains were then rinsed
twice with dH2O and transferred to 30% sucrose in dH2O for 3 days
at 4 C, with the solution changed after the initial 12 h. Brains were
then coronally sectioned at 150 mm into 30% sucrose in dH2O using
a vibratome (Leica VT10005). Sections were mounted onto slides
coated with 0.3% gelatin in dH2O. Once dried, slides were immersed
in 40% sucrose in dH2O and allowed to dry for 72 h in the dark.
Slides were then rinsed three times in dH2O for 10 min, immersed
in Golgi-Cox Development Solution for 7 min, and rinsed three
times in dH2O for 10 min. Slides were then dehydrated through
graded ethanols followed by Histoclear (HS-200, National
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medium (EMS). The dendrites and spines of hippocampal CA1 py-
ramidal neurons were traced using a 100 objective and Neuro-
lucida. Three dendrites per neuron and three neurons per mouse
were analyzed. The spine densities of from second to fourth order
dendrites were analyzed using NeuroExplorer (MBF Biosciences).
2.15. Statistical analysis
All in vitro and in vivo cellular and morphological analyses were
performed in a blinded manner. Based on published work and our
previous studies assessing small molecule efﬁcacy, we anticipated
greater variability in the drug-treated groups and chose our sample
sizes to allow statistical differentiation of groups exhibiting differ-
ences of 20% or more. Statistical signiﬁcance was determined using
a one-way Analysis of Variance (ANOVA) and either Dunnett’s,
Dunn’s, or Bonferroni’s multiple comparison post-hoc tests with
InStat 3 or StatView Software. In cases in which data did not follow
a normal distribution, a Mann-Whitney or Kruskal-Wallis test
(nonparametric ANOVA) with Dunn’s multiple comparison test was
applied. p-values reported in the text are for comparisons using
post-hoc testing after signiﬁcant main effects were determined
using an ANOVA. Speciﬁc post-hoc tests used are provided in the
ﬁgure legends. Statistical outliers were deﬁned as values that were
3 or more standard deviations from the mean. Using this criterion,
only one data point in one experiment was eliminated (Fig. 6I,
BDNF response). Results are expressed as group mean ± SEM and
statistical signiﬁcance was set at p  0.05.
3. Results
3.1. Identiﬁcation and characterization of a small molecule with
neurotrophic activity
Our laboratories previously applied in silico screening based on
BDNF loop II, thought to be a key domain that mediates binding to
and activation of TrkB, to identify non-peptide, small molecule TrkB
activators (Massa et al., 2010). A second screening experiment using
a substantially larger compound library was undertaken to broaden
the chemical range of active scaffolds and ﬁnd compounds with
improved pharmacologic characteristics, in particular, blood brain
barrier penetration. The same BDNF loop II pharmacophore which
previously yielded LM22A-4 and other active compounds (Massa
et al., 2010) was utilized in an Accelrys Catalyst screen of a new
library derived from the Chemnavigator database (now within
Sigma-Aldrich, Milwaukee, WI) of ~5.5 million commercially
available compounds, with an average of ~30 conformers tested per
compound. 2670 compounds with a low-energy conformer
compatible with the pharmacophore and with MW  500 Da were
further ﬁltered using Accelrys Cerius2 for compliance with Lipinski
criteria (Lipinski et al., 2001) and predicted blood brain barrier
penetration score. Finally, the highest scoring compound models
were visually screened for potential steric interference not
accounted for by the pharmacophore model, within a general
model of loop II interaction with a shallow receptor region. Of
these, 18 compounds were tested for neurotrophic activity using
E16 hippocampal neurons under conditions in which survival de-
pends on exogenous BDNF. Four compounds (LM22B 9, -10, -17
and 24) had biological activity that was similar or signiﬁcantly
above BDNF maximal efﬁcacy, 22% of the compounds tested (data
not shown). LM22B-10 (MW 485 Da, structure in Fig. 1A) had the
highest efﬁcacy of these andwas further characterized for its effects
on cell survival, neurite outgrowth, and dendritic spine density.
LM22B-10 exhibited maximum neurotrophic survival activity
levels that were higher than those maximally achieved with BDNF(53± 7.2% above BDNF at 0.7 nM) and NT-3 (91 ± 8.6% above NT-3 at
0.7 nM) with an EC50 of 200e300 nM (Fig. 1B, C). The effects of both
BDNF and NT-3 reached a plateau between 0.175 and 0.35 nM
(5e10 ng/ml), with stable responses up to the maximum concen-
tration tested (1.85 nM). Survival activity for LM22B-10 reached a
plateau by ~1000 nM and was stable up to 4000 nM, the maximum
concentration tested. Thus, 0.7 nM for BDNF and NT-3, and 1000 nM
for LM22B-10 were chosen as standard concentrations for most of
the subsequent studies. Cell death, as reﬂected by TUNEL staining,
was reduced by 68 ± 2.3% with BDNF treatment, 64 ± 4.3% with NT-
3, and 85 ± 1.4% with LM22B-10 (Fig. 1D). Maximal survival in the
presence of BDNF and NT-3 together approximated that of either NT
alone, and remained signiﬁcantly less than that achieved with
LM22B-10 at 48 h in culture (Fig. 1E). Neurites of E16 hippocampal
neurons had average lengths of 20e30 mm at 2 days in vitro and
were unaffected by BDNF and NT-3 at concentrations of
0.04e1.85 nM, a range over whichmaximal effects on survival were
reached. In contrast, LM22B-10 at 1000 nM induced neurites of
signiﬁcantly larger average lengths, up to ~40 mm (p  0.01
compared to culture medium; Fig. 1F). LM22B-10 effects on neurite
outgrowth began at 125e250 nM, with no signiﬁcant change be-
tween 500 and 1000 nM, and had an apparent EC50 in the same
range as its effects on survival (Fig. 1C,E). LM22B-10-induced neu-
rites reached maximum lengths within ~7 days, while neurite
length increased more gradually in hippocampal neurons treated
with BDNF, NT-3, or a combination of the two at concentrations that
induced maximal survival, approaching the plateau level produced
by LM22B-10 over 15e20 days (Fig. 1G). Themedian dendritic spine
density of hippocampal neurons was also signiﬁcantly increased
with both BDNF and LM22B-10 treatment (Fig. 1H,I; p ¼ 0.01 and
p < 0.001, respectively, compared to culture medium, p < 0.01 for
BDNF versus LM22B-10). Additionally, the cumulative frequency
distribution of spines was increased with LM22B-10 (p  0.00002
compared to culture medium and p  0.0003 compared to BDNF;
two-sample Kolmogorov-Smirnoff (K-S) test), and showed an in-
crease with BDNF which did not reach signiﬁcance (p  0.055
compared to culture medium; Fig. 1J).
3.2. LM22B-10 binds selectively to TrkB and TrkC
To address the binding speciﬁcity of LM22B-10, three ap-
proaches were used: recombinant NT receptor binding of the
compound measured by mass spectrometry, cell-based NT
competition binding assays, and radioligand inhibition screening of
pharmacologically relevant receptors. In the ﬁrst approach, bead-
bound receptor extracellular domain/Fc chimeras (TrkA-Fc, TrkB-
Fc, TrkC-Fc and p75NTR-Fc) were incubated with LM22B-10
(250e2000 nM) and the fraction of bound compound was
measured (as in refs (Massa et al., 2010; Pochet et al., 2011;
Zehender and Mayr, 2007)). LM22B-10 bound to TrkB-Fc and
TrkC-Fc in a dose-dependent manner, but binding to TrkA-Fc or
p75NTR-Fc was not detected (Fig. 2A). In addition, cognate NT
competition studies were performed using 3T3-cells expressing
one of each of the NT receptors. LM22B-10 inhibited binding of
BDNF to TrkB-expressing cells (p¼ 0.0023 for the main effect of the
compound on NT binding) and NT-3 to TrkC-expressing cells
(p ¼ 0.0003), but had no detectable effect on NGF or BDNF binding
to cells expressing TrkA (p ¼ 0.7767) or p75NTR (p ¼ 0.4356;
Fig. 2BeE). Interestingly, although LM22B-10 binding to TrkB was
similar, or perhaps slightly less than, binding to TrkC (Fig. 2A),
LM22B-10 (1 mM) displaced BDNF (1 nM) nearly completely
(Fig. 2B) while NT-3 (1 nM) binding was reduced by only ~40%
(Fig. 2C). The NT binding regions of TrkB and TrkC are structurally
similar however there are signiﬁcant variances, for example, they
differ enough to disallow BDNF binding to TrkC. Thus, differences in
Fig. 1. Neurotrophic activities of LM22B-10. A, Chemical structure of LM22B-10. B, Photomicrographs of b-tubulin III-immunostained (top row) and TUNEL-stained (bottom row)
E16 mouse hippocampal neurons in culture medium (CM) alone or medium containing BDNF, NT-3 or LM22B-10 (#10) for 48 h. Scale bar, 10 mm. C, Neuron survival dose-response
curves for BDNF, NT-3 and LM22B-10. Cell counts were normalized to those achieved with 20 ng/ml (~0.7 nM) BDNF. For BDNF and LM22B-10, values for each concentration were
obtained from 12 experiments and derived from 57-67 and 31e69 wells (n). For NT-3, values were obtained from 6 experiments and derived from 39 wells (n). BDNF and NT-3
responses plateau between 0.175 and 0.35 nM (5e10 ng/ml), with stable responses up to the maximum tested, 1.85 nM, LM22B-10 survival activity plateaus at ~1000 nM and
is stable up to the maximum tested concentration of 4000 nM. D, Quantitation of the fraction of TUNEL-positive/DAPI-staining cells shows that LM22B-10 decreases the number of
TUNEL-positive cells as does BDNF and NT-3 with a signiﬁcantly greater effect of LM22B-10 than the NTs. *p  0.05 versus BDNF and **p  0.01 versus CM. A total of 58e105 ﬁelds
(n) per condition derived from 4 experiments were counted. E, Quantitation of survival of hippocampal neurons treated with CM, 0.7 nM BDNF, 0.7 nM NT-3, BDNF and NT-3
together, or 1000 nM LM22B-10. Maximal survival is not increased when the NTs are added together. LM22B-10 induces greater survival than BDNF plus NT-3, as well as each
individually. A total of 30e60 wells (n) per condition derived from 3-9 assays were counted. **p  0.01, compared to CM. F, Neurite outgrowth dose responses for BDNF
(0.046e1.85 nM), NT-3 (0.046e1,85 nM) and LM22B-10 (0.0325e1000 nM). Cultured E16 mouse hippocampal neurons were treated as indicated for 48 h and immunostained for b-
tubulin III. Neurite outgrowth at each concentration was derived from 88-377 neurites (n) from 6 experiments for BDNF, 135e177 neurites (n) from 5 experiments for NT-3, and,
189e966 neurites (n) obtained from 4 experiments for LM22B-10. **p  0.01 compared to CM. G, E16 mouse hippocampal neurons were treated with CM, 0.7 nM BDNF, 0.7 nM NT-3
or 1000 nM LM22B-10 for 2, 7, 14 or 21 days and immunostained for b-tubulin III. Neurite outgrowth in 4 experiments from each time point and condition was derived from 96-202
neurites (n) for Day 2, 203e308 neurites (n) for Day 7, 174e300 neurites (n) for Day 14, and 96e165 neurites (n) for Day 21. ***p  0.001 for each condition compared to
CM. þp  0.05 and þþp  0.01 for NTs compared to LM22B-10 at different time points. H-I, LM22B-10 increases spine density in vitro. Cultured hippocampal neurons at 14 DIV were
transfected with reporter plasmid (EGFP), neurons were treated with 0.7 nM BDNF or 1000 nM LM22B-10 for 24 h and the spine density measured using Neurolucida. At least 10
random confocal images from 3 independent experiments for each condition were measured. H, Photomicrographs of spines on dendrite segments of hippocampal neurons treated
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of signaling pathways may not be unexpected. The structural cor-
relates of this remain to be investigated. Finally, a radioligand
competition binding assay (performed by Cerep, Inc.) was used to
evaluate whether LM22B-10 interfered with the binding of 57 G-
protein coupled peptide and non-peptide receptors to their
respective ligands, including adenosine, common neurotransmit-
ters and ion channels (see Suppl. Table 1 for the complete list). In
this screen, >50% inhibition of control speciﬁc binding indicated
signiﬁcant binding by the test compound. LM22B-10 at 10 mM (the
standard screening concentration) signiﬁcantly inhibited only
5HT5a and the dopamine transporter. Since 10 mM is a high con-
centration which could lead to non-speciﬁc effects, LM22B-10
binding at 1000 nM, a concentration at which the compound pro-
duced maximum neurotrophic effects, was evaluated with selected
receptors including 5HT5a and dopamine transporter. At this con-
centration, LM22B-10 did not signiﬁcantly inhibit any of the re-
ceptors examined (see Suppl. Table 2). Together these studies
demonstrate that LM22B-10 binds toTrkB and TrkC directly and can
displace BDNF from TrkB and NT-3 from TrkC. Furthermore, its
binding is selective for TrkB and TrkC, and within a standard set of
pharmacologically well-characterized receptors, little, if any, sig-
niﬁcant binding occurs.
3.3. LM22B-10 induces biologic activities via TrkB and TrkC
To determinewhether the binding selectivity LM22B-10 for TrkB
and TrkC correlated with its biological effects, survival responses of
3T3-cells expressing TrkA, B, or C, or p75NTR, and hippocampal
neurons were examined. Adding BDNF or LM22B-10 to serum-free
medium did not support survival of the 3T3 parent line, which does
not express p75NTR or Trk receptors (Fig. 3A,B), nor did it affect
survival of 3T3-p75NTR cells (Fig. 3C). However, cells engineered to
stably express Trks responded substantially to their cognate ligands
(Fig. 3A). LM22B-10 produced a small increase in survival of 3T3-
TrkA cells, while cells expressing TrkB or TrkC responded to a
substantially greater degree (Fig. 3A). Quantiﬁcation revealed that
LM22B-10 increased survival in a dose-dependent manner in each
cell type (Fig. 3D): its effects in 3T3-TrkA cells were small with a
maximum increase of 62 ± 9% relative to baseline, which was ~35%
of NGF’s effects; substantially larger increases occurred in 3T3-TrkB
and 3T3-TrkC cells with respective maximum increases of
123 ± 36% (~78% of BDNF) and 147 ± 35% (~109% of NT-3) relative to
baseline.
Since NT-p75NTR binding may stimulate anti-survival mecha-
nisms under some circumstances and interactions between Trks
and p75NTR may inﬂuence the outcomes of ligand binding, it was of
interest to further investigate the potential role of the differences in
binding to p75NTR of LM22B-10 relative to the NTs in the differential
survival responses observed in neurons. To begin to examine this
question, p75NTR was expressed in 3T3-TrkB and -TrkC cells (Fig. 3E)
which were then exposed to BDNF, NT-3 or LM22B-10 in serum-
free medium. Expression of p75NTR in both 3T3-TrkB and 3T3-
TrkC cells signiﬁcantly reduced the increase in survival that oc-
curs in the presence of BDNF and NT-3 respectively (each p  0.05
for p75NTR vs. control plasmid), but had no effect on LM22B-10
responses (Fig. 3F, G). It is clear, particularly in the case of TrkB
cells (Fig. 3F), that if the response of TrkB/p75NTR-expressing cells to
BDNF was considered to be the maximum neurotrophic response,
then the response to LM22B-10 would be substantially greaterwith BDNF or #10 or untreated (CM). Scale bar, 10 mm. I-J, Quantitation of dendritic spine d
frequency distribution (J, p ¼ 0.055, BDNF compared to CM; p  0.000016, LM22B-10 com
noted, statistical signiﬁcance for each analysis was determined using ANOVA with post-hoc(56 ± 20% increase). These results are consistent with the
involvement of p75NTR signaling in the observed differences be-
tween the NTs and LM22B-10 in the support of neuronal survival,
though other factors may contribute.
To further examine whether LM22B-10’s neurotrophic activity
was dependent on its activation of TrkB and TrkC, survival re-
sponses were assessed in the presence of the kinase inhibitor
K252a. K252a substantially inhibited the survival effects of the NTs
in TrkB and TrkC cells (Fig. 3H, I), and had a similar effect on LM22B-
10-induced survival, suggesting that the compound’s activities
depend on Trk kinase activation. Of note, although K252a has also
been shown to block mixed-lineage kinases, thereby inhibiting JNK
activation and activating AKT and ERK through the Src pathway
(Roux et al., 2002; Walter et al., 2011), K252a alone did not affect
survival in this cellular system. BDNF effects on survival in hippo-
campal cell cultures were nearly completely inhibited by K252a,
whereas the LM22B-10 response was inhibited by ~60% (Fig. 4A).
Though this ﬁnding could indicate non-Trk mediated effects of
LM22B-10, there are potential Trk mechanisms that are insensitive
to K252a, for example, truncated TrkB isoforms, which completely
lack tyrosine kinase activity, have been reported to support NT-
mediated calcium signaling that is insensitive to K252a (Rose
et al., 2003).
The ﬁnding that survival responses to BDNF and NT-3 were
reduced in 3T3-cells co-expressing p75NTR and Trks, but were un-
affected by LM22B-10 suggested that LM22B-10’s greater effects on
neuronal survival and/or neurite outgrowth than those caused by
NTs could be due, at least in part, to its lack of engagement of
p75NTR. This possibility, and the dependence of LM22B-10 effects
on Trks, was further explored in a neuronal context by analyzing
whether the effect of NTs or LM22B-10 on survival and neurite
outgrowth were affected by inhibiting TrkB or TrkC via anti-Trk
antibodies, or by up- or down-regulating p75NTR in hippocampal
neurons. Applying antibodies speciﬁc to TrkB or TrkC to hippo-
campal neurons partially inhibited the survival promoted by their
cognate NT ligands and by LM22B-10 (each p  0.001 for TrkB and
TrkC antibody vs. control; Fig. 4B, C). Neurite outgrowth, which was
not increased at 2 DIV in the presence of BDNF or NT-3, was un-
changed by TrkB or TrkC antibodies (not shown), but both anti-
bodies decreased the promotion of neurite length seen with
LM22B-10 (p  0.01 vs. non-immune serum), consistent with
compound action through each receptor (Fig. 4D). Interestingly, a
p75NTR antibody had the opposite effect on neurite outgrowth in
the presence of LM22B-10, causing a signiﬁcant increase relative to
non-immune serum treatment (p  0.01), which was not observed
with the NTs (Fig. 4D). The presence of the p75NTR antibody
signiﬁcantly promoted survival above that induced by the NTs and
LM22B-10 (p  0.05 for BDNF versus non-immune serum;
p  0.001 for NT3 and LM22B-10 vs. non-immune serum; Fig. 4E),
consistent with a previous report of reversal of NT-mediated death
with a p75NTR antibody (Friedman, 2000). Furthermore, p75NTR
siRNA treatment of hippocampal neurons that resulted in an ~86%
knockdown of p75NTR protein (Fig. 4F) signiﬁcantly increased sur-
vival with NT and LM22B-10 exposure (p  0.001 vs. control siRNA)
(Fig. 4G). p75NTR knockdown also increased neurite outgrowth at 2
DIV in response to LM22B-10 (p  0.05 versus control siRNA)
similar to that observed with p75NTR antibody (Fig. 4H). This effect
was not observed with the NTs. Interestingly, the presence of BDNF
and/or NT-3 signiﬁcantly inhibited LM22B-10’s enhancement of
neurite development (Fig. 4I) and survival (data not shown).ensity (I; **p ¼ 0.011 and ***p < 0.001 versus CM, Mann Whitney test) and cumulative
pared to CM; p  0.00035, LM22B-10 compared to BDNF; K-S test). Unless otherwise
Dunnett or Bonferroni multiple comparison test.
Fig. 2. LM22B-10 binds to TrkB and TrkC. A, Protein A-decorated Dynabeads™ coupled to TrkA, TrkB, TrkC or p75NTR-extracellular domain/Fc were incubated with increasing
concentrations of LM22B-10 and bound compound determined by LC-MS/MS. n ¼ 9 from 3 experiments at each concentration. B-E, NIH-3T3 cells expressing TrkB, TrkC, TrkA, or
p75NTR, as indicated, were incubated with increasing concentrations of the indicated NT in the absence (white circles) or presence (black circles) of 1000 nM LM22B-10. Symbols
represent average ﬂuorescent signal after background (i.e., binding to cells lacking expressed receptors) subtraction, as described in Methods. n ¼ 16e18 wells from 8e9 exper-
iments at each concentration. Signiﬁcant rightward shift of binding curves by the compound is observed only with TrkB and TrkC expressing cells. Statistical signiﬁcance was
determined using ANOVA with post-hoc Bonferroni multiple comparisons test. *p  0.05, **p  0.01 and ***p  0.001 compared to each NT concentration without the presence of
LM22B-10.
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at TrkB and TrkC, and/or inhibitory p75NTR or Trk signaling that is
not induced by LM22B-10.
The biological effects of some neurotrophic agentsmay occur via
G protein-coupled receptor (GPCR)-mediated transactivation of
Trks involving Src family kinases (Daub et al., 1997; Lee and Chao,
2001; Lee et al., 2002; Luttrell and Luttrell, 2004). Trk activation
by this mechanism has been reported for adenosine via the aden-
osine A2A receptor, and PACAP via its receptor PACR1 (Lee and Chao,
2001; Lee et al., 2002; Shi et al., 2010). This raised the possibility
that LM22B-10 might activate a GPCR or another receptor, which
then activates TrkB/TrkC. To evaluate this possibility, the effects of
the Src inhibitor PP2 on survival, neurite outgrowth and TrkB
phosphorylation of hippocampal neuron cultures treated with
LM22B-10 or NTs was determined. PP2 (10 mM) did not affect
neuron survival mediated by NTs or LM22B-10 or neurite
outgrowth induced by LM22B-10 (Fig. 4J, K). In addition, PP2
decreased tyrosine phosphorylation of TrkB and TrkC elicited by
adenosine and PACAP27, but did not affect that induced by LM22B-
10 or the NTs (Fig. 4L). Together, these results suggest that TrkB and
TrkC activation by LM22B-10 is not due to a Src kinase-mediated
Trk transactivation mechanism.3.4. LM22B-10 promotes neurite outgrowth in an inhibitory
environment
The central nervous system (CNS) undergoes limited repair after
injury, due in part to the presence of inhibitors of neuriteoutgrowth that prevent axonal regeneration, including myelin-
associated glycoprotein (MAG) and chondroitin sulfate pro-
teoglycans (CSPGs) (Berry, 1982; McKerracher et al., 1994;
Niederost et al., 1999). NTs may or may not facilitate axonal
growth in the presence of myelin-component inhibitors (Spencer
et al., 2008; Wang et al., 2002; Williams et al., 2005) depending
upon the interplay of outgrowth-supporting Trk-mediated
signaling and growth cone collapse-promoting p75NTR-mediated
signaling, and varying with cell type and physiologic state (Naska
et al., 2010). A prior study found that a peptide designed to acti-
vate TrkB without effects on p75NTR could reverse MAG inhibition
of cerebellar neurite outgrowth, while BDNF did not (Williams
et al., 2005), suggesting that isolated stimulation of Trks may
support process outgrowth in an inhibitory environment. The
activation of Trks and increases in neurite outgrowth induced by
LM22B-10 without apparent engagement of p75NTR suggested that
it might also have this effect. To test this hypothesis, LM22B-10
effects on neurite outgrowth of cultured hippocampal neurons (2
DIV) were assessed in the presence of MAG or CSPG (Fig. 5A, B).
Under these conditions BDNF and NT-3 had no effect on neurite
outgrowth in culture medium alone (similar to Figs. 1E, 4D and H),
while each appeared to produce a small sparing effect on the
decrement in outgrowth observed in the presence of CSPG (30 ± 6%
over culture medium for BDNF, 23 ± 7% for NT-3), and were each
entirely ineffective in the presence of MAG (Fig. 5B). In marked
contrast, LM22B-10 signiﬁcantly increased neurite length in the
inhibitory environments: 92 ± 8%with CSPG and 57 ± 6%withMAG
(both p  0.001). These ﬁndings suggest that LM22B-10
Fig. 3. LM22B-10 promotes cell survival preferentially through TrkB and TrkC. A-D, Trk-expressing NIH-3T3 cells were incubated in serum-free medium in the presence of the
indicated NTs or LM22B-10 for 72e96 h and survival was measured using the ViaLight assay. A, Representative images showing that LM22B-10 supports survival of 3T3-TrkB and
3T3-TrkC cells, but not 3T3 and 3T3-TrkA cells. Scale bar, 10 mm. B, Quantitation of native 3T3 cells shows no support of survival by 0.7 nM BDNF or 1000 nM LM22B-10. C, For 3T3-
p75NTR cells, neither BDNF nor LM22B-10 supports survival. D, Survival dose-response curves for LM22B-10 in 3T3 cells expressing TrkA, B or C. For 3T3-TrkA cells, NGF was the
positive control (deﬁned as 100% activity); for 3T3-TrkB, BDNF was the positive control; for 3T3-TrkC, NT-3 was positive control; *p  0.05, **p  0.01 compared to CM alone. E-G,
3T3-TrkB or 3T3-TrkC cells were transfected (80e88% efﬁciency) with control (DsRed) or p75 plasmid (p75-RFP). E, Western blotting shows 3T3-TrkB and 3T3-TrkC cell expression of
p75NTR. F-G, BDNF or NT-3, but not LM22B-10, treatment causes a signiﬁcant decrease of survival in cells with p75-expression vs control. *p  0.05 compared to control
plasmid; þþp  0.01 or þþþp  0.001 compared to CM. H, Survival analysis of 3T3-TrkB cells treated with 0.7 nM BDNF or 1000 nM LM22B-10 with or without 200 nM K252a for
48 h; **p  0.01 compared to BDNF or #10; þþþp  0.001 compared to CM. I, Survival analysis of 3T3-TrkC cells treated with 0.7 nM NT-3 or 1000 nM LM22B-10 with or without
200 nM K252a for 48 h; **p  0.01 compared to NT-3 or #10; þþþp  0.001 compared to CM. For each determination, n ¼ 10e32 wells derived from 5-14 independent experiments
were analyzed. Statistical signiﬁcance was determined using an ANOVA with Dunnett’s (B, C and D) or Bonferroni (F-I) post-hoc multiple comparison tests.
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activation that are distinct from those of BDNF and NT-3
To begin to investigate the differences in biologic activity pro-
ﬁles between LM22B-10 and the NTs, their patterns of induction of
Trk and downstream effector phosphorylation were examined. In
TrkA-3T3 cells, LM22B-10 did not induce detectable phosphoryla-
tion of TrkA at Y490 or Y791, or of AKT or ERK1/2, in marked
contrast to NGF (Fig. 6A). In 3T3-TrkB cells, BDNF, at a concentrationstimulating its maximal biological activity, increased TrkB phos-
phorylation at Y515, Y705, and Y817, and promoted phosphoryla-
tion of ERK, AKT, and PKC. LM22B-10, at a concentration that
induces its maximal neurotrophic activity (1000 nM), also induced
detectable TrkB phosphorylation at each of these sites as well as
AKT, ERK and PKC phosphorylation, though to a substantially lesser
degree than BDNF (Fig. 6B, C). The pattern of lesser TrkB activation
induced by LM22B-10 relative to BDNF was also observed using
TrkB immunoprecipitation followed by phospho-tyrosine detection
with the pY99 antibody (Fig. 6D, E). These results were similar to
those previously observed for the TrkB partial agonist LM22A-4
Fig. 4. LM22B-10 functions through TrkB and TrkC. A, Survival analysis of hippocampal neurons treated with 0.7 nM BDNF or 1000 nM LM22B-10 with or without 200 nM K252a
for 48 h. For BDNF, 12 wells (n) derived from 6 experiments; for LM22B-10, 19 wells (n) derived from 6 experiments; ***p  0.001 for with or without K252a
comparison; þþþp  0.001 compared to CM. B, C, Survival of hippocampal neurons treated with CM, 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 with or without TrkB or TrkC
antibodies. For TrkB antibody experiments, 37e42 wells (n), derived from 5 experiments were assessed. For TrkC antibody 12 wells (n), derived from 4 experiments were assessed;
***p  0.001 for with or without Trk antibodies; þþþp  0.001 compared to CM. D, Neurite outgrowth analysis of hippocampal neurons treated with CM or 1000 nM LM22B-10
with or without TrkB, TrkC or p75NTR antibodies for 48 h. For each condition 33e338 neurites (n), derived from 3 experiments were assessed; **p  0.01 compared to CM plus non-
immune serum; þþþp  0.001 compared to CM. E, Survival of hippocampal neurons treated with CM, 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 with or without p75NTR
antibody. 15e16 wells (n), derived from 4 experiments were assessed; *p  0.05 and ***p  0.001 compared to the respective CM plus non-immune serum group; þþþp  0.001
compared to CM. F-H, Hippocampal neurons were transfected with control siRNA or p75NTR siRNA. F, Representative Western blot demonstrating that p75NTR siRNA decreases
p75NTR expression by ~86% relative to control. G, Survival analysis of hippocampal neurons treated with CM, BDNF, NT-3 or LM22B-10 with control siRNA or p75NTR siRNA. p75NTR
siRNA causes a signiﬁcant increase in survival with all treatments. 18 wells (n), derived from 3 experiments were assessed; *p  0.05 and **p  0.01 compared to the respective
control siRNA group; þþþp  0.001 compared to CM. H, Neurite outgrowth analysis of hippocampal neurons treated with CM, 0.7 nM BDNF or 1000 nM LM22B-10 with control
siRNA or p75NTR siRNA for 48 h. For each condition 75e323 neurites (n), derived from 3 experiments were assessed; *p  0.05 compared to the respective control siRNA
group; þþþp  0.001 compared to CM. I, Neurite outgrowth of cells treated with CM, 0.7 nM BDNF, 0.7 nM NT-3 with or without 1000 nM LM22B-10 as indicated. Addition of NTs
alone or in combination decreased the neurite length promotion induced by LM22B-10. Neurite outgrowth for each condition was derived from 83-531 neurites (n) obtained from 3
separate experiments; *p  0.05 and ***p  0.001 compared to LM22B-10. Statistical signiﬁcance was determined using an ANOVAwith a post-hoc Bonferroni multiple comparisons
test in A-H and a post-hoc Dunnett’s multiple comparisons test in I. J-L, Cultured E16 hippocampal neurons treated with CM, BDNF, NT-3 or LM22B-10 without or with 10 mM PP2 for
48 h (J, K) and 1 h (L). J, Survival analysis: PP2 did not signiﬁcantly affect survival in any of the treatment conditions; 16 wells (n), derived from 4 experiments were
assessed; þþp  0.01 compared to CM. K, Neurite outgrowth analysis. For each condition 89e750 neurites (n), derived from 3-6 experiments were assessed; þþp  0.01 compared
to CM in J and K. L, For Western analyses, the ratios of phospho-anti-TrkY490 to total panTrk were determined and normalized to the CM group. Samples run in Lanes 1e6 were from
cultures that were not treated with PP2, those run in Lanes 7e12 were treated with PP2. Other treatments are as follows, Lanes 1,7: CM; Lanes 2, 8: BDNF; Lanes 3,9: NT3; Lanes 4,10:
LM22B-10; Lanes 5,11: adenosine; Lanes 6,12: PACAP. Quantitation of BDNF and NT3 is not shown. n ¼ 6 independent protein preparations measured on 18 western blots. Statistical
signiﬁcance was determined using an ANOVA with a post-hoc Dunnett’s test in J-L or Student’s t-test in L for comparison between with and without PP2 groups. *p  0.05
comparing with and without PP2. þp  0.05 compared to CM.
T. Yang et al. / Neuropharmacology 110 (2016) 343e361352
Fig. 5. LM22B-10, but not BDNF or NT-3, promotes neurite outgrowth in an
inhibitory environment. A, Hippocampal neurons in CM containing 0.1% FBS with or
without MAG-Fc at 25 mg/ml or CSPG at 1 mg/ml, in the presence of the 0.7 nM BDNF,
0.7 nM NT-3 or 1000 nM LM22B-10. Cultures were maintained for 24 h before staining
for b-Tubulin III. Scale bar, 10 mm. B, Mean neurite length was determined from 248-
650 neurites under each culture condition obtained from 5 separate experiments. MAG
and CSPG signiﬁcantly inhibit neurite outgrowth and LM22B-10 stimulates neurite
outgrowth in these inhibitory environments. ***p  0.001 compared to CM plus CSPG
or MAG; þþþp  0.001 compared to CM alone. Statistical signiﬁcance was determined
using an ANOVA with post-hoc Bonferroni multiple comparisons test.
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measurement of kinase activity in TrkB immunoprecipitates, which
demonstrated signiﬁcant activation induced by both BDNF and
LM22B-10 (p  0.01 and 0.05, respectively, versus culture medium;
Fig. 6F).
TrkB phosphorylation at Y515 promotes recruitment of the
adaptor protein Shc, which is crucial for NT-dependent cell growth
and differentiation (Reichardt, 2006). Previous studies demon-
strated that BDNF and LM22A-4, a small molecule TrkB ligand,
induced TrkB activation and Shc recruitment in human
cementoblast-like cells (Kajiya et al., 2014). In the present study
using the same cell system, LM22B-10 promoted Shc recruitment to
TrkB (Fig. 6G) consistent with its triggering activation of the re-
ceptor andwith the activation of Ras-MAPK and PI3K-AKT signaling
induced by the compound (Fig. 6C).
Although LM22B-10 bound to the extracellular domains of TrkB
and TrkC, induced TrkB/C phosphorylation and downstream
signaling, had its biological effects inhibited by TrkB/C extracellular
domain antibodies, and activated TrkB/C independently of Src
kinase-mediated transactivation, the possibility remained that the
compound binds to an unknown target that is capable of inducing a
non-Src-dependent transactivation of Trk. To address this possi-
bility, the effects of LM22B-10 on Trk phosphorylation were
examined in HEK-293 cells expressing full-length wild-type TrkB or
chimeric TrkA/B receptors (Perez et al., 1995; Zaccaro et al., 2001).
In the TrkA/B chimera 1.4B, the extracellular domain of TrkA is
fused with the intracellular domain of TrkB, and in the chimeric
receptor 4.1B the TrkB IgG-C2 domain, which is required for BDNF-TrkB activation (Zaccaro et al., 2001), is replaced by the TrkA IgG-C2
region. Western blot analysis using anti-Trk674/675, which recog-
nizes phosphorylated tyrosine residues at the catalytic domain of
Trks indicating Trk kinase activity, was performed on cells
expressing these constructs and treated with NGF (0.7 nM), BDNF
(0.7 nM) or LM22B-10 (1000 nM) (Marsh et al., 2003). In HEK-
293 cells expressing full-length WT TrkB, BDNF and LM22B-10
triggered increased tyrosine phosphorylation, while NGF did not
(Fig. 6H,I). In contrast, in cells expressing the TrkA/B chimeric re-
ceptors, NGF promoted phosphorylation, but BDNF and LM22B-10
did not (Fig. 6J,K). These ﬁndings suggest that LM22B-10 activa-
tion requires the TrkB extracellular domain and are not consistent
with Trk transactivation studies (Lee and Chao, 2001; Lee et al.,
2002; Shi et al., 2010) in which transactivation persists in the
presence of the TrkA extracellular chimera. Interestingly, these
ﬁndings also indicate that the IgG-C2 domain or a nearby region
may be involved in LM22B-10-mediated receptor activation.
While LM22B-10 induced a TrkB phosphorylation pattern that
differed from that of BDNF, it induced a pattern very similar to that
of NT-3 at homologous Trk sites in 3T3-TrkC cells (Fig. 6L,M). A plot
of mean NT versus compound phosphorylation signal ratios for
each cell type (Fig. 6N) further illustrated the close relationship
between LM22B-10-induced patterns and those associated with
NT-3 (mean slope ¼ 1.51, r2 ¼ 0.78) and variances with BDNF re-
sponses (mean slope ¼ 0.032, r2 ¼ 0.018). Interestingly, the pattern
of phosphorylation induced by LM22B-10 was similar in TrkC and
TrkB cells (compare Fig. 6C, M).
LM22B-10 might differentially stimulate receptor activation and
signaling in the presence of multiple receptors found in a neuronal
context, or there might be signiﬁcant differences in signaling ki-
netics relative to the NTs. Therefore, it was of interest to examine
Trk and its downstream signaling intermediates over time
following stimulation in hippocampal neurons. BDNF exposure
produced signiﬁcantly greater phosphorylation of TrkBY515,
TrkBY705 and TrkBY817 than that induced by LM22B-10, with BDNF
producing near plateau levels within 10 min, and LM22B-10
requiring 60 min to achieve signiﬁcant increases (Fig. 7A, DeF).
Exposure to NT-3, which activates both TrkB and TrkC (Ryden and
Ibanez, 1996) (Fig. 7B,G) resulted in greater phosphorylation of
TrkC at sites Y516 and Y820 relative to the compound, though this
difference was not statistically signiﬁcant (Fig. 7B,H). Similar to
TrkB, there was an apparent delay of signiﬁcant TrkC phosphory-
lation levels of ~60 min for LM22B-10 while NT-3 produced sig-
niﬁcant increases within 10 min. LM22B-10 signiﬁcantly increased
phosphorylation of AKT and ERKs above baseline with similar ki-
netics as BDNF and NT-3 (Fig. 7C, I, J). In response to the NTs, ERK1/2
activation was signiﬁcantly greater than with LM22B-10 but AKT
activation was not (Fig. 7I, J). Phosphorylation of PKC occurred to a
similar degree amongst the treatments (Fig. 7C, K). Thus, stimula-
tion of neurons with concentrations of LM22B-10 which induce
maximal survival and neurite outgrowth produced less phosphor-
ylation than the NTs at TrkBY515/TrkCY516, similar to the pattern
observed in 3T3-TrkB cells (Fig. 6C, K), as well as similar or lesser
phosphorylation of AKT and ERKs, similar to the responses of
neurons to LM22A-4, a ﬁrst generation compound which binds to
and activates TrkB but not TrkC (Massa et al., 2010). In addition, the
kinetic proﬁles for TrkBY490, AKT and ERK phosphorylation are
highly similar between LM22B-10 and LM22A-4. Of note, a modest
and similar increase in phosphorylation of PKC was detected in
response to both NTs and LM22B-10 (Fig. 7K), consistent with their
promotion of phosphorylation at TrkBY817/TrkCY820 which are
coupled to this pathway via PLCg activation (Reichardt, 2006).
Immunostaining in hippocampal cultures showed no apparent
differences in localization of p-TrkB or pTrkC between NT- and
LM22B-10-treated cells. Signiﬁcant increases in pTrkB and signaling
Fig. 6. LM22B-10 selectively induces TrkB, TrkC, AKT and ERK phosphorylation in 3T3-Trk cells. 3T3-TrkA, 3T3-TrkB and 3T3-TrkC cells were grown in DMEM supplemented
with 10% FBS to 50e60% conﬂuence, exposed to NTs or LM22B-10 (#10) for 48 h in serum free medium containing 50% PBS and 50% DMEM, incubated in 50% PBS/50% DMEM
without NTs or LM22B-10 for 6 h, and ﬁnally exposed to 20 ng/ml (0.7 nM) NT or 1000 nM LM22B-10 in serum-free DMEM for 1 h. Cell lysates were analyzed by immunoblotting,
immunoprecipitation, and kinase activation assays. Representative Western blots show contiguous lanes and white spaces separate panels from different gels; total protein bands
are re-probed from the corresponding phospho-lanes. Immunoblots were quantitated by determining the ratios of phospho(p)-protein over total protein and normalized to the CM
group. A, In 3T3-TrkA cells, NGF induced TrkA, AKT and ERK phosphorylation while LM22B-10 did not. B, C, In 3T3-TrkB cells, BDNF and LM22B-10 induced TrkB, AKT, ERK and PKC
phosphorylation. For each determination, n ¼ 10e14 independent protein preparations were measured on 20e28 western blots (each sample run in duplicate and the results
averaged). Statistical signiﬁcance was determined using an ANOVA with post-hoc Dunn’s multiple comparisons test.*p  0.05, **p  0.01 and ***p  0.001 compared to CM. D, E, F,
80e100 mg/ml of extracted protein was immunoprecipitated with TrkB antibody, and half of the protein was retained for Western blotting and the other half saved for kinase activity
determination. D, E, Western blot membranes were probed with either pY99 or TrkB antibody. Bands were analyzed using UN-SCAN-IT software and the ratio of pY99 to TrkB was
normalized to CM. n ¼ 13 protein preparations and 26 western blots, each preparation was run in duplicate and the normalized values averaged. F, Kinase assay was performed as
described in Methods, n ¼ 10 independent protein preparations with values from two immunoprecipitations of each sample averaged. Each treatment was compared to CM using
the Mann-Whitney U test (*p  0.05, **p  0.01, ***p  0.001). G, Human cementoblast-like cells were treated with BDNF (0.7 nM) or LM22B-10 (1000 nM) and protein extracts were
immunoprecipitated with TrkB antibody. Western blot membranes were probed with either Shc or TrkB antibody and the ratio of Shc to TrkB was normalized to CM. n ¼ 13 protein
preparations and 26 western blots, each preparationwas run in duplicate and the normalized values averaged. Each treatment was compared to CM using the Mann-Whitney U test
(*p  0.05, ***p  0.001). H-K, HEK-293 cells were transfected with TrkB full length plasmid (TrkB-WT), TrkA/B chimeras 1.4B (TrkA/B-1.4B) and TrkA/B chimeras 4.1B (TrkA/B-4.1B)
then exposed to 0.7 nM indicated NTs or 1000 nM LM22B-10. Cell lysates were analyzed by immunoblotting. I-K, Western analyses were quantitated by determining the ratios of p-
Trk over total Trk protein and normalized to the CM group. For TrkB-WT, n ¼ 22 independent protein preparations. For TrkA/B-1.4B, n ¼ 13 independent protein. For TrkA/B-1.4B,
n ¼ 8 independent protein preparations. Statistical signiﬁcance was determined using an ANOVA with post-hoc Dunn’s multiple comparisons test. **p  0.01 and ***p  0.001
compared to CM. L,M, In 3T3-TrkC cells, NT-3 and LM22B-10 induce TrkC, AKT and ERK phosphorylation, but not PKC. For each determination, n ¼ 10e14 independent protein
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lesser induction by LM22B-10, which reached statistical signiﬁ-
cance above baseline for Y817 (p  0.05) but did not reach signif-
icance for Y515 (Fig. 7L, M, N). TrkC activation studies in
hippocampal neuron cultures showed signiﬁcant increases in pTrkC
signal stimulated by LM22B-10 and NT-3 at both Y516 (p  0.01)
and Y820 (p  0.01 for NT-3 and p  0.05 for LM22B-10), with
apparent lesser inductions by LM22B-10 (Fig. 7L, O, P). Together,
these studies reveal similarities between LM22B-10 and LM22A-4
compounds, and differences relative to the NTs with respect to
the initiation and extent of signaling suggesting the possibility of
discrete activation mechanisms utilized by different ligand classes.
3.6. AKT, ERK and PLCg activation contribute to neurotrophic
activity of LM22B-10
Since LM22B-10 produces less or similar acute AKT and PKC
activation compared to the NTs, and signiﬁcantly less ERK activa-
tion, while exhibiting greater effects on survival and neurite
outgrowth, the possibility of the involvement of other Trk-
dependent signaling, and the question of the role of AKT, ERK and
PLCg activations in the compound’s biologic effects arise. In TrkB-
and TrkC-expressing 3T3 cells and hippocampal neurons, NT and
LM22B-10 survival-inducing activities were signiﬁcantly reduced
by LY294002, a selective inhibitor of PI3K (an upstream activator of
AKT); PD98059, a MAPKK inhibitor (an upstream activator of ERK);
and U73132, a PLCg inhibitor (an upstream activator of PKC)
(Fig. 8A, B). LY294002 and U73132 each reduced LM22B-10 effects
on survival of both 3T3-TrkB and eTrkC cells to 1.5e1.8 times the
culture medium background (p  0.01 for TrkB cells; p  0.05 for
TrkC cells), while PD98059 was more effective (p  0.01 for TrkB
and TrkC cells; Fig. 8A). This pattern of signal reductionwas distinct
from that observed with the NTs possibly due to differences be-
tween the NTs and LM22B-10 with respect to mechanisms of Trk
activation, and/or, may indicate that LM22B-10 acts through addi-
tional targets. In addition, the inhibitors were generally less effec-
tive in reducing BDNF/TrkB cell survival to baseline than they were
with NT-3/TrkC cells, possibly reﬂecting the stronger activation of
downstream signaling afforded by BDNF in TrkB cells. In contrast to
TrkB-3T3 cells, the inhibitors reduced BDNF’s survival effects on
hippocampal neurons to a greater extent than those of LM22B-10.
Interestingly, the abundant short-latency neurite outgrowth of
hippocampal neurons induced by LM22B-10 is inhibited by
LY294002 and U73132 (both p  0.001), but not PD98059 (Fig. 8C),
suggesting that the augmentation of neurite outgrowth produced
by the compound may be independent of the activation of ERKs,
and could involve other non-Trk targets.
3.7. LM22B-10 activates TrkB, TrkC, AKT and ERK in vivo
To further examine the biologic effects of LM22B-10 and
determine its suitability as a therapeutic candidate, the blood brain
barrier penetration of the compound was determined via different
routes of administration. Brain levels in mice weremeasured by LC-
MS/MS 0.5e8 h after intraperitoneal (IP), oral gavage (OG), and IN
administration. Following IN administration at 5 mg/kg, brain
levels reached ~45 nM (Fig. 9A), a concentration that showed
neurotrophic activity in vitro. IP injection produced brain levels in
the 600e1500 nM range 1e8 h after administration (Fig. 9B), while
OG administration resulted in a similar peak at 3 h and producedpreparations measured on 20e28 western blots (each sample run on duplicate blots and th
hoc Dunn’s multiple comparisons test. *p  0.05, **p  0.01 and ***p  0.001 compared to CM
illustrate the close relationship between LM22B-10-induced patterns with those associatedlevels in the ~800 nM range at 8 h. The lowest dose that produced
concentrations in brain which were similar to those which pro-
duced biologic activity in vitro (5 mg/kg IN) and a 10-fold lower
dose (0.5 mg/kg) were then utilized for evaluation of LM22B-10
activation of Trk signaling in C57BL/6J mice. Following 7 days of
once daily IN administration to adult mice with harvesting 1 h after
the last dose, quantitative western blotting revealed dose-
dependent activation of TrkB and TrkC, as well as AKT and ERK in
the hippocampus (overall signaling vs. dose, F2,117 ¼ 31.882,
p < 0.0001) (Fig. 9C) and striatum (overall signaling vs. dose,
F2,117 ¼ 16.453, p < 0.0001) (Fig. 9D). This result is consistent with
in vivo target engagement by LM22B-10, and given the low dose
and small cell populations within each sampled brain area that
express TrkB and TrkC, may indicate a particularly robust signaling
response.
3.8. LM22B-10 activates synaptic TrkB and TrkC and increases pre-
and post-synaptic proteins and spine density in aged mice
Marked decreases in hippocampal neuron dendritic spine den-
sity occur in normal aging, are associatedwithmemory dysfunction
(Lahiri et al., 2005; von Bohlen und Halbach et al., 2008; von Bohlen
und Halbach et al., 2006), and can be reversed by BDNF (Kramar
et al., 2012; Lynch et al., 2008; Rex et al., 2007). Since LM22B-10
increased spine density in vitro, and since it was found to engage
its signaling targets in brain tissue, it was of interest to determine
whether it might decrease spine loss in aged mice. Male 15e17
month old C57Bl/6J mice were administered LM22B-10 at 50mg/kg
IP and 5 mg/kg IN simultaneously to maximize compound brain
levels, once daily for 30 days, and, 1 h after the last dose, brains
were harvested. Hippocampal synaptosomes from these mice
showed increased phosphorylation at TrkBY817 and TrkCY820 in
response to LM22B-10 (both p  0.05 versus vehicle), again
consistent with in vivo CNS target engagement (Fig. 10A, B). LM22B-
10 also increased levels of the pre- and post-synaptic proteins
synaptophysin and PSD95 (both p  0.05 versus vehicle; Fig. 10C,
D). Consistent with these synaptic marker results, on basal and
apical dendrites of hippocampal CA1 neurons in these aged mice,
LM22B-10 increased spine cumulative frequency distributions
(p  3  108 for apical and p  7.5  106 for basal versus vehicle;
two-sample K-S test) and density (p  0.01 and p  0.05, respec-
tively; Fig. 10E, F, G). The functional consequences of these
biochemical and structural changes remain to be explored.
4. Discussion
Characterization of LM22B-10 has revealed several signiﬁcant
similarities and differences with NT action, and with the actions of
previously described small molecule Trk ligands. The most striking
of these are the ﬁndings that LM22B-10 promotes cell survival and
accelerates neurite outgrowth in signiﬁcant excess of that induced
by the native NTs, and produces neurite growth resistant to
inhibitory signals, despite apparently low levels of canonical NT
signaling pathway activation. Multiple lines of evidence suggest
that LM22B-10 functions as an active TrkB and TrkC ligand,
including: detection of direct binding to TrkB and TrkC; inhibition
by the compound of BDNF and NT-3 binding to their cognate re-
ceptors; the dependence of trophic activity on TrkB or TrkC
expression; kinase inhibitor K252a inhibition of neurotrophic ac-
tivities; inhibition of activity by blocking antibodies speciﬁc to thee results averaged). Statistical signiﬁcance was determined using an ANOVA with post-
. N, Mean NT vs compound phosphorylation signal ratios for 3T3-TrkB or 3T3-TrkC cells
with NT-3 (circles) and variances with BDNF (triangles), responses.
Fig. 7. LM22B-10 induces TrkB, TrkC, AKT and ERK activation in hippocampal neurons in culture. A-C, Representative western blot images showing induction of TrkB, TrkC, AKT
and ERK phosphorylation in E16 hippocampal neurons incubated 0.7 nM NTs or 1000 nM LM22B-10 for the indicated time durations. D-K, Western analyses were quantitated by
determining the ratios of phospho (p)-protein over total protein and normalized to CM group. D, pTrkBY515; E, pTrkBY705; F, pTrkBY817; G, pTrkCY516; H, pTrkCY820; I, pAKT; J, pERK; K,
pPKC. For each determination in D-K, n ¼ 10 independent protein preparations measured on 20 western blots (each sample run on duplicate blots and the results averaged).
Statistical signiﬁcance was determined using an ANOVA with post-hoc Dunn’s multiple comparisons test. *p  0.05, **p  0.01 and ***p  0.001 compared to CM. All panels show
contiguous lanes, total protein images were reprobed from the corresponding phospho-lanes and white space separates panels from different gels. L-P, Immunohistochemical
analysis of TrkB and TrkC phosphorylation in hippocampal neurons. Cultured E16 hippocampal neurons were incubated with 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 for
1 h. Cells were then immunoﬂuorescently stained with the indicated phospho-speciﬁc Trk antibodies. Total ﬂuorescence intensity was quantitated using UN-Scan-it software; ratios
of total ﬂuorescence intensity over total cell numbers were calculated. L, Representative immunostaining images. Scale bar, 10 mm. M-P, Immunostaining quantitation. For each
determination, n ¼ 15e18 ﬁelds total derived from 3 independent experiments. Statistical signiﬁcance was determined using an ANOVAwith post-hoc Dunn’s multiple comparisons
test. *p  0.05, **p  0.01, ***p  0.001 compared to CM.
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adaptor protein; the ability of BDNF and NT-3 to inhibit/compete
with LM22B-10’s augmentation of neurite outgrowth; and the
reduction of biologic activities with inhibition of induced down-
stream signaling pathways.
The ﬁndings that LM22B-10 produces neurotrophic effects that
are not identical to those of NTs (relatively greater effects on sur-
vival and neurite outgrowth; neurite outgrowth on inhibitorysubstrates) and that its signaling dynamics differ from those of NTs
(slower Trk activation and reduced but signiﬁcant activation of
downstream signaling) raise two mechanistic possibilities. First,
LM22B-10, as a compound designed to correspond to only one of
multiple NT domains interacting with Trk, and not capable of
binding to p75NTR, activates Trk receptors throughmechanisms that
are, at least in part, different from those triggered by NTs. At this
point relatively few Trk partial agonists and/or allosteric
Fig. 8. LM22B-10’s effects on survival depend on downstream signaling. A, 3T3-TrkB and 3T3-TrkC cells were incubated with 0.7 nM BDNF or 1000 nM LM22B-10 for 72e96 h in
the presence or absence of the PI3K inhibitor LY294002 (LY, 10 mM), MAPKK inhibitor PD98059 (PD, 50 mM) or PLCg inhibitor U73132 (1 mM). Cell survival was assessed using
ViaLight. B, Survival of E16 hippocampal neurons incubated with 0.7 nM BDNF or 1000 nM LM22B-10 for 48 h in the presence or absence of LY, PD or U73132. For each survival
determination, n ¼ 14e26 wells derived from 7-11 independent experiments were analyzed. C, Neurite outgrowth of E16 hippocampal neurons incubated with 0.7 nM BDNF or
1000 nM LM22B-10 for 48 h in the presence or absence of the K252a (200 nM), 10 mM LY, 50 mM PD, or 1 mM U73132. For each condition, 39e196 neurites (n), derived from 3
experiments were assessed. Statistical signiﬁcance was determined using an ANOVA with post-hoc Dunnett’s multiple comparisons test. *p  0.05, **p  0.01 and ***p  0.001
compared to CM with either BDNF or #10.
T. Yang et al. / Neuropharmacology 110 (2016) 343e361 357modulators exist, thus, the limited characterization available limits
any general expectation regarding the biological and signaling
repertoire expected of such compounds. An important second
possible mechanism is that LM22B-10 might bind to and activate
unidentiﬁed non-Trk targets that are capable of transactivating Trks
and promoting their downstream signaling. This possibility was
made less likely by our inability to detect known mechanisms
involving Src-dependent Trk transactivation, and the dependence
of LM22B-10 TrkB activation on the presence of the TrkB extracel-
lular domain. Together, these ﬁndings suggest that binding of
LM22B-10 to TrkB and TrkC promotes biologic activities to a large,
but not necessarily exclusive extent, through Trk receptors and
coupled activation of signaling pathways. As is the case for all
growth factor ligands, all small molecules and all drugs, alternative
mechanisms cannot be completely ruled out and additional targetstudies will be required.
Both binding and biologic activities appeared to be relatively
selective for TrkB and TrkC. Though LM22B-10 produced a small
increase in survival of TrkA-expressing cells, it did not detectably
bind to, or alter NT binding to TrkA. These ﬁndings might be due to
the greater sensitivity of detection of biological activity versus
detection of ligand binding. Similarly, activation of three primary
downstream signaling intermediates (PI3K/AKT, MAPK/ERK and
PLCg/PKC) was not observed in cells expressing TrkA alone. Thus,
the minor bioactivity associated with TrkA expressionmight be due
to compound-induced signaling below detectable levels, though
alternative mechanisms, including action through an unidentiﬁed
non-Trk target, remain possible. Further, LM22B-10 did not bind to
p75NTR, and there was no trophic effect in p75NTR-3T3 cultures.
With expression of individual Trks, in a non-neuronal context
Fig. 9. LM22B-10 penetrates the BBB, and induces TrkB and TrkC phosphorylation and downstream signaling. A, B, Brain levels of LM22B-10, determined by LC-MS/MS, in mice
given a single intraperitoneal (IP), oral gavage (OG), intranasal (IN) or IP þ IN dose (n ¼ 3 mice/time point). C, D, LM22B-10 or saline control was administered intranasally to 3
month old mice at the indicated dosages for 7 days. Western blots of extracts of hippocampus (C) and striatum (D) were quantitated by determining the ratios of phospho (p)-
protein over total protein and normalized to respective CM groups; n ¼ 5 mice, with three independent western blots averaged per animal. Statistical signiﬁcance was determined
using an ANOVA with post-hoc Dunn’s multiple comparisons test. *p  0.05 and **p  0.01 compared to saline.
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LM22B-10 were signiﬁcantly different from those induced by
BDNF/TrkB, but similar to NT-3/TrkC (Fig. 6). However, in neurons,
compound-induced acute TrkB, TrkC, ERK1/2 and AKT signaling
were substantially lower than that produced by either BDNF or NT-
3. This ﬁnding is similar to our previous work characterizing
LM22A-4, a small molecule ligand that binds only to TrkB and
functions as a partial agonist with maximal neurotrophic and TrkB
signaling activities lower than those triggered by BDNF (Massa
et al., 2010), in contrast to LM22B-10. Detailed kinetic analysis of
responses in hippocampal neurons revealed delayed activation of
TrkB by LM22A-4 relative to that stimulated by BDNF while kinetics
of AKT and ERK1/2 were similar between these two compounds up
to 4 h after dosing. In the present study, LM22B-10 presents a
similar kinetic proﬁle. The ﬁnding that neurite outgrowth is resis-
tant to MAPKK inhibition with PD98059 is of particular interest.
This result was unexpected, as ERK1/2 activation may be associated
with neurite outgrowth and PD98059 has been found to inhibit
neurite growth in some stimulation paradigms (Pang et al., 1995;
Sjogreen et al., 2000); however the effects of MAPK inhibition
may vary, and may even be reversed, depending on the state of the
cells and stimuli utilized (Althini et al., 2004; Wiklund et al., 2002).
Since LM22B-10 produces neurite-growth effects that are sub-
stantially accelerated relative to those caused by BDNF or NT-3,
even in combination, while at the same time stimulating lowerlevels of activation of TrkB and TrkC and their primary downstream
signaling modules, other non-classical mechanisms may be
involved. These could include quantitatively or qualitatively novel
TrkB/TrkC signaling patterns, due to: qualitative differences in re-
ceptor activation or deactivation kinetics, or turnover, in particular
over longer periods of time; activation ratios; or recruitment of
parallel/non-canonical pathways, resulting in synergistic neuro-
trophic effects not normally occurring with BDNF/NT-3 signaling. In
addition, binding of LM22B-10 to TrkB/TrkC in the absence of
p75NTR binding and its anti-trophic effects, might alter overall
signaling patterns resulting in a net increase in neurite outgrowth,
suggested by the further enhancement of neuritogenesis and sur-
vival with p75NTR antibody blockade and knock-down, and resis-
tance of LM22B-10 neurotrophic activity to the introduction of
p75NTR expression. Finally, though perhaps less likely, LM22B-10
might bind to one or more unknown targets distinct from TrkB/
TrkC that, by coincidence, have a substantial impact on neurite
outgrowth. Further analysis of LM22B-10/Trk kinetics, interactions
with p75NTR, possible non-Trk targets and downstream signaling
dependencies will be needed to construct a detailed model of
LM22B-10 action.
Another feature of LM22B-10 biological activities of potential
practical importance, consistent with its initiation of novel
signaling patterns, is its overcoming of neurite inhibitor effects of
MAG and CSPG, which is not achieved by the native NTs. Given the
Fig. 10. LM22B-10 increases dendritic spine density in aged mice in vivo. A-D,
LM22B-10 or saline was administered 50 mg/kg/day IP and 5 mg/kg/day IN to 15e17
month old C57BL/6J mice for 30 days, and synaptosomal protein extracts from
hippocampi were assessed by Western blot. The ratio of phospho-protein over total
protein or indicated protein over actin was determined. A, pTrkBY817; B, pTrkCY820; C,
synaptophysin; D, PSD95. n ¼ 5 mice, with three independent western blots averaged
per animal. E, Spine density of hippocampal CA1 neurons of aged mice was determined
in Golgi-stained dendrites using Neurolucida. Spines were counted from at least three
dendrites per neuron and three neurons per mouse, n ¼ 10e12 neurons from 3 mice/
group. *p  0.05 and **p  0.01 compared to vehicle group, Mann-Whitney U test.
Scale bar, 10 mm. F, G, Cumulative frequency distribution of dendritic spines of aged
mice. For apical, ***p  0.00000003 and, for basal, ***p  0.0000075, vehicle versus
#10, K-S test.
T. Yang et al. / Neuropharmacology 110 (2016) 343e361 359suggested roles for MAG and CSPG in inhibiting neurite outgrowth
in spinal cord injury (SCI) (Busch and Silver, 2007; Giger et al.,
2008), it will be of interest to determine if LM22B-10 or its de-
rivatives might promote neurite outgrowth in vivo in SCI models.
Previous work has led to the development of small moleculescapable of functioning as ligands that activate speciﬁc Trk receptors
(Jang et al., 2010a, 2010b, 2007; Maliartchouk et al., 2000; Massa
et al., 2010; Scarpi et al., 2012), and activation of TrkA and TrkB
by amitriptyline has been reported (Jang et al., 2009). To our
knowledge, LM22B-10 constitutes the ﬁrst small molecule capable
of preferentially activating TrkB and TrkC, and also the ﬁrst to have
neurotrophic activity substantially exceeding that of the native NTs.
The structural bases of Trk activation by these various small mol-
ecules remain unclear. Some have been reported to promote re-
ceptor dimerization, and evidence has been presented for different
Trk binding sites for several molecules, both intra- and extracellular
(Longo and Massa, 2013). Of note, the likely region of interactions
between NT family b-turn loop II and Trks is the juxtamembrane
extracellular domain, which to date has not undergone crystallo-
graphic or other detailed structural analysis (Wehrman et al., 2007).
Trk activation by small molecules may also occur via binding to
pre-formed Trk dimers. Previous studies have shown that most
TrkB receptors are present in a pre-formed homodimeric form
before ligand binding in living cells (Shen and Maruyama, 2012), as
is TrkA (Shen and Maruyama, 2011), and small molecules may
activate dimeric receptors (Jiang and Hunter, 1999; Livnah et al.,
1999). Furthermore, there are alternative models of dimeric re-
ceptor activation by which small molecules could exert their ef-
fects, including: 1) binding to monomeric receptors inducing a
conformational change leading to dimerization and activation; and
2) binding to receptor sites other than the ligand-binding domain
to cause dimerization via allosteric mechanisms (for review see
Longo and Massa (2013)).
Further work on the structural changes induced in Trks by these
small molecules will be needed to determine whether a common
mechanism is present. Should this be the case, it might be possible
to develop ‘designer’ small molecule ligands that preferentially
activate each of the three possible pairs of Trks (A-B, A-C, B-C) and
thereby offer, with potentially less off-target effects and more
consistent distribution than using multiple monospeciﬁc com-
pounds, providing a best ﬁt for targeting various mechanisms of
interest or pathological processes, depending on the populations of
neurons involved. For example, TrkB and TrkC agonist antibodies
have been found to improve morphological and functional out-
comes in a mouse model of Charcot-Marie-Tooth peripheral neu-
ropathy with the combination of TrkB and TrkC antibodies
achieving greater effects than either alone (Sahenk et al., 2010).
Moreover, a TrkB/C activator might affect a desired population of
neurons while avoiding the pain upregulation mechanisms trig-
gered by TrkA activation. Other disease relevant neuronal pop-
ulations expressing both TrkB and TrkC include those degenerating
in Alzheimer’s, Parkinson’s and Huntington’s diseases and trials
with LM22B-10 in corresponding mouse models are underway.
Among various drug development strategies, a promising
modern approach consists of designing multi-target-directed li-
gands for complex diseases with functional synergy (Guzior et al.,
2015). The ability of LM22B-10 to trigger activation of TrkB, TrkC
and their numerous downstream signaling intermediates in vivo in
the hippocampus and striatum and its ability to increase spine
density in aged mice raise the possibility that LM22B-10 class li-
gands might be applied to disorders involving loss of dendritic
spines and synaptic dysfunction across populations of neurons
expressing TrkB and TrkC, which includes a wide range of neuro-
logical and neuropsychiatric disorders. (Longo and Massa, 2013;
Seraﬁni et al., 2014; Zhang et al., 2015).
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